Pfizer raises estimates for 2021 sales of COVID-19 vaccine to $33.5 billion By Reuters
© Reuters. FILE PHOTO: A person walks past a Pfizer logo amid the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., April 1, 2021. REUTERS/Carlo Allegri/File Photo
(Reuters) -Pfizer Inc on Wednesday raised its forecast for sales of the COVID-19 vaccine that it developed with Germany’s BioNTech by 28.8% to $33.5 billion, as countries scramble to secure supply of the shots.
The company said the raised sales forecast of the vaccine is based on signed deals for 2.1 billion doses this year.
The drugmaker’s previous forecast in May of $26 billion was based on deals signed for 1.6 billion doses. Wall Street analysts were broadly in line with that forecast at $28.51 billion, according to nine analysts polled by Refinitiv.
Since then, Pfizer (NYSE:) has said it expects to produce as much as 3 billion doses this year.
Expenses and profit from the vaccine are split 50-50 between Pfizer and BioNTech.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Military training jet crashes in Texas, injuring both pilots
A military training jet crashed Sunday in a Dallas suburb, injuring the two pilots and damaging three homes. Both pilots…
Key data on U.S. J&J, Moderna COVID-19 boosters ‘weeks away,’ Fauci says By Reuters
© Reuters. FILE PHOTO: Top infectious disease expert Dr. Anthony Fauci responds to accusations by Sen. Rand Paul (R-KY) as…